ChromaCode Finds $12M For Molecular Diagnostics Efforts

Carlsbad-based ChromaCode, a developer of molecular diagnostics technology, announced on Thursday that it has raised $12M in a Series B funding round. The funding was led by New Enterprise Associates (NEA), and also included Domain Associates and Okapi Ventures. ChromaCode says its software and assay technology leverages existing real-time PCR instruments and uses digital signal processing to dramatically improve molecular analysis. Alex Dickson, Ph.D., former SVP of Strategic Initiatives at Illumina, has joined as Executive Chairman , and Justin Klein, M.D., a Partner at NEA, has joined the company's board, both as a result of the funding round.